EDAP to Report Second Quarter 2016 Financial Results on August 25, 2016
August 11 2016 - 7:30AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that it plans to release financial
results for the second quarter ended June 30, 2016 on Thursday,
August 25, 2016, during pre-market hours.
Company management will host a conference call on
Thursday, August 25, 2016 at 8:30 a.m. ET to discuss the results
and provide an update on recent business developments, including
the sales of Ablatherm® Robotic HIFU in United States. To
participate in the call, please dial 1-888-348-6419 in the U.S., or
1-412-902-4235 internationally. The conference ID number is
10091258. A live webcast of the conference call will be available
on the investor relations page of the Company’s corporate website
at www.edap-tms.com.
After the live event, the webcast will remain
available on EDAP’s website through September 27, 2016. In
addition, a dial-in replay of the call will be available until
September 3, 2016. The telephone replay can be accessed by calling
1-877-870-5176 in the U.S. or 1-858-384-5517 internationally.
Please use event passcode 10091258.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for
high-intensity focused ultrasound (HIFU) for prostate tissue
ablation in the U.S. and for treatment of localized prostate cancer
in the rest of the world. HIFU treatment is shown to be a minimally
invasive and effective option for prostatic tissue ablation with a
low occurrence of side effects. Ablatherm is generally recommended
for patients with localized prostate cancer (stages T1-T2) who are
not candidates for surgery or who prefer an alternative option, or
for patients who failed radiotherapy treatment. Ablatherm is
approved for commercial distribution in Europe and other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press
release may contain forward-looking statements. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties, including matters not yet known
to us or not currently considered material by us, and there can be
no assurance that anticipated events will occur or that the
objectives set out will actually be achieved. Important factors
that could cause actual results to differ materially from the
results anticipated in the forward-looking statements include,
among others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Sep 2024 to Oct 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Oct 2023 to Oct 2024